<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="102424">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01789060</url>
  </required_header>
  <id_info>
    <org_study_id>2013-01-047</org_study_id>
    <nct_id>NCT01789060</nct_id>
  </id_info>
  <brief_title>p-AKT Expression on Clinical Outcomes in Malignant Lymphoma</brief_title>
  <official_title>The Impact of Activated p-AKT Expression on Clinical Outcomes in Malignant Lymphoma : A Clinicopathological Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <authority>South Korea: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PI3K(phosphatidylinositol 3-kinase)/AKT pathway is an important oncogenic signaling pathway.
      However, clinical information about the significance of p-AKT expression in malignant
      lymphoma is not fully understood yet. In this study, we investigated the overexpression of
      p-AKT and its prognostic implication in malignant lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recently, among diverse oncogenic signaling pathways, a number of studies have focused on
      the significance of oncogenic PI3K/AKT (phophatidylinositol 3-kinase/serine-threonine
      kinase, also known as protein kinase B [PKB]) pathway. PI3K(phosphatidylinositol
      3-kinase)/AKT pathway phosphorylates and activates AKT as phosphorylated AKT (p-AKT) and
      plays a critical role promoting malignant phenotype and has prognostic significance in
      various solid cancers.

      However, a systematic approach on the impact of p-AKT overexpression on clinical outcomes
      has not been performed in malignant lymphoma.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Difference of overall survival according to p-AKT status in malignant lymphoma</measure>
    <time_frame>study entry</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subgroup analysis of overall survival according to histologic subtypes (GCB vs non GCB)</measure>
    <time_frame>study entry</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Subgroup analysis of overall survival according to International Prognostic Index risk groups</measure>
    <time_frame>study entry</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">262</enrollment>
  <condition>Malignant Lymphoma</condition>
  <condition>P13K-AKT Pathway Deregulation</condition>
  <arm_group>
    <arm_group_label>p-AKT</arm_group_label>
    <description>p-AKT immunohistochemical staining,high p-AKT expression (upper quartile), low p-AKT expression (lower 3 quartiles)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>p-AKT immunohistochemical staining</intervention_name>
    <description>p-AKT staining on the adequate paraffin-embedded biopsy specimen or unstained slides</description>
    <arm_group_label>p-AKT</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      paraffin-embedded biopsy specimen or unstained slides for immunostaining of p-AKT
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with malignant lymphoma who are treated in a tertiary hospital in Korea (Samsung
        Medical Center)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. the patients were pathologically confirmed of malignant lymphoma, according to the
             World Health Organization classification;

          2. the patients had adequate paraffin-embedded biopsy specimen or unstained slides for
             immunostaining of p-AKT.

        Exclusion Criteria:

        1. Primary central nervous system lymphoma was excluded in this study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Won Seog Kim, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 7, 2013</lastchanged_date>
  <firstreceived_date>February 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Won Seog Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
